Results 71 to 80 of about 2,343,487 (194)

Targeting EPAS-1/HIF-2α Pathway to Address Endocrine Resistance in Luminal A Type Breast Cancer

Translational Oncology
Background: Tamoxifen is most often used as the first treatment for luminal A breast cancer; however, one-third of the patients are resistant to it. Numerous studies have shown that hypoxia contributes to drug resistance and is related to poor clinical ...
Enzhi Luo, Seongmin Lee, Neeraj manvi agarwal, Junjeong Choi   +3 more
doaj   +1 more source

Overcoming tamoxifen resistance in oestrogen receptor-positive breast cancer using the novel thiosemicarbazone anti-cancer agent, DpC

, 2020
Background and Purpose: Breast cancer is the leading cause of death in women worldwide, with resistance to current therapeutic strategies, including tamoxifen, causing major clinical challenges and leading to more aggressive and metastatic disease.
Patric J. Jansson, Lim, Syer C, Kovacevic, Zaklina, Rumeza Hanif, Park, Kyung Chan, Des R. Richardson, Zaklina Kovacevic, Hanif, Rumeza, Sundus N. Maqbool, Kyung Chan Park, Maqbool, Sundus N, Richardson, Des R, Jansson, Patric J, Syer C. Lim   +13 more
core   +1 more source

The association between neural crest‐derived glia and melanocyte lineages throughout development and disease

Developmental Dynamics, EarlyView.
Abstract Neural crest cells are a transient cell population that emerges from the dorsal neural tube during neurulation and migrates extensively throughout the embryo. Among their diverse derivatives, glial cells (such as Schwann and satellite ganglionic cells) and melanocytes represent two major lineages. In vitro studies suggested they share a common
Chaya Kalcheim
wiley   +1 more source

PARP14-mediated glycolysis enhances Tamoxifen resistance in estrogen receptor + breast cancer cells

Discover Oncology
Background Resistance to Tamoxifen is a major challenge in the therapeutic management of estrogen receptor (ER) + breast cancer (BC). Glycolysis, as reported, exerts a crucial influence on the regulation of Tamoxifen resistance in BC, highlighting the ...
Wenju Mo, Fanrong Zhang, Chen Wang, Xiaowen Ding, Lili Ren   +4 more
doaj   +1 more source

Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells.

PLoS ONE, 2019
MiR-873/CDK3 has been shown to play a critical role in ERα signaling and tamoxifen resistance. Thus, targeting this pathway may be a potential therapeutic approach for the treatment of ER positive breast cancer especially tamoxifen resistant subtype ...
Xiumei Zhang, Bingfeng Zhang, Panhong Zhang, Lihui Lian, Lianlian Li, Zhihong Qiu, Kai Qian, An Chen, Qiongqing Liu, Yinjie Jiang, Jiajun Cui, Bing Qi   +11 more
doaj   +1 more source

Targeting Pin1 by All-Trans Retinoic Acid (ATRA) Overcomes Tamoxifen Resistance in Breast Cancer via Multifactorial Mechanisms

Frontiers in Cell and Developmental Biology, 2019
Breast cancer is the most prevalent tumor in women worldwide and about 70% patients are estrogen receptor positive. In these cancer patients, resistance to the anticancer estrogen receptor antagonist tamoxifen emerges to be a major clinical obstacle ...
Songyin Huang, Yang Chen, Zhi-Mei Liang, Zhi-Mei Liang, Na-Na Li, Na-Na Li, Yujie Liu, Yujie Liu, Yinghua Zhu, Yinghua Zhu, Dingzhun Liao, Xiao Zhen Zhou, Kun Ping Lu, Yandan Yao, Yandan Yao, Man-Li Luo, Man-Li Luo   +16 more
doaj   +1 more source

AKT-Induced Tamoxifen Resistance is Reversed by RRM2 Inhibition

, 2014
Acquired tamoxifen resistance develops in the majority of hormone-responsive breast cancers and frequently involves overexpression of the PI3K/AKT axis.
Mehta, Kshama R., Livesey, John C., Peterson, David, Shah, Khyati N., Faridi, Jesika S., Evangelista, Marie   +5 more
core   +1 more source

TARBP2-Enhanced Resistance during Tamoxifen Treatment in Breast Cancer

, 2019
Tamoxifen is the most widely used hormone therapy in estrogen receptor-positive (ER+) breast cancer, which accounts for approximately 70% of all breast cancers.
Yu-Jhen Lyu, Yao-Lung Kuo, Pai-Sheng Chen, Jie-Ning Li, Hsin-Yi Huang, Hung-Yu Sun, Ming-Yang Wang, Bo-Rong Chen, Chiao Lo   +8 more
core   +1 more source

Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer [PDF]

, 2010
In women with estrogen receptor(ER)- and ErbB2(HER2)-positive breast cancer, a vicious cycle is established between ER mechanisms of action and the growth factor receptor network, leading to enhanced cell proliferation and endocrine resistance.
Bauerfeind, Ingo, Elling, Dirk, Heinemann, Volker   +2 more
core   +1 more source

Tamoxifen resistance mechanisms in breast cancer treatment

, 2020
Therapies targeting estrogen receptor (ER) are being widely used to treat ER+ breast cancer patients. Despite early detection and improved survival outcomes, tamoxifen resistance, either intrinsic or acquired- is a major obstacle in effective disease ...
Asima Tayyeb
core   +1 more source